All In Biotech

Drug Trial Radar · NCT01596751

Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jul 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

67

Actual

Start

Jul 12, 2012

Primary completion

Jul 5, 2017

Study completion Jul 5, 2019

Sponsor

Lead sponsor
Hope Rugo, MDAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Susan G. Komen Breast Cancer Foundation; Plexxikon
First posted
May 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the Phase 1b portion of the study is to determine the best dose of PLX3397 when given in combination with standard dose eribulin (Halaven™). The purpose of the Phase 2 portion of the study is to find out what effects, good and/or bad, these drugs have on patients and their metastatic breast cancer.

Conditions

  • Metastatic Breast Cancer

Interventions

  • PLX3397Drug

    Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration

  • EribulinDrug

    Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of PLX3397 Given in Combination With Standard Dose Eribulin in Participants With Metastatic Breast Cancer (Phase 1b)Time frame: Up to Day 21
  2. Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) (Phase Ib)Time frame: Up to Day 21
  3. Percentage of Total Phase II Participants With Chemotherapy Pre-Treated Triple Negative Metastatic Breast Cancer Who Are Progression Free at 3 MonthsTime frame: Up to 3 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, San Francisco

    San Francisco, California

  • Duke University Cancer Center

    Durham, North Carolina

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.